Humacyte

Humacyte, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. It offers its products to the cardiovascular, cosmetic, soft tissue reconstruction, neurosurgical, and orthopedic markets. The company was founded by Laura E. Niklason and Juliana L. Blum in October 13, 2004 and is headquartered in Durham, NC.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Humacyte reports progress in trials and collaborations, poised for growth

Humacyte's Q4 2022 performance reflects a strong cash position, progress in key trials, and preparations for commercial activities. The company's strengths lie in innovative programs, strategic collaborations, and promising trial outcomes. Challenges include enrollment disruptions, regulatory complexities, and strategic planning considerations.
Opportunities for Humacyte include expanding its product portfolio, pursuing accelerated approvals, and leveraging successful trial outcomes for partnerships and market entry. With a focus on commercial readiness and visibility enhancement, Humacyte is poised for growth and advancement in the biotechnology sector.

Humacyte advances HAV trials, secures funding for commercial launch

Humacyte's Q1 2023 performance reflects promising advancements in vascular trauma treatments and strategic collaborations for product development.
While the company faces challenges in financing and regulatory processes, opportunities lie in market expansion and innovative partnerships.
Overall, Humacyte's progress in trials and financial stability position it well for future growth and potential market success.

Humacyte progresses HAV program, eyes growth through strategic collaborations

Humacyte's Q2 2023 earnings call highlighted advancements in the HAV program, positive outcomes in trauma indications, and strategic collaborations. While facing financial challenges with no revenue generated, the company's strong partnerships and funding support present opportunities for future growth and innovation.

Humacyte plans BLA submission for HAV after positive trial results

Humacyte's Q3 2023 performance reflected no revenue, a net loss of $26.0 million, and $100 million in cash and cash equivalents.
The Human Acellular Vessel (HAV) demonstrated superior outcomes in clinical trials and real-world applications, positioning it well for market adoption.
While financial challenges exist, the company's strategic focus on commercial launch preparation and real-world evidence collection presents growth opportunities.
Navigating market acceptance, reimbursement, and competition will be key for Humacyte's success in the biologics space.

Humacyte achieves FDA milestone with HAV, eyes market expansion

Humacyte made significant progress with FDA acceptance of BLA for HAV, showcasing superior outcomes and cost-saving potential.
Financially, the company had a strong cash position and aims for improved margins despite increased expenses in 2024.
Challenges include managing increased expenses and achieving superiority across patient groups, while opportunities lie in market expansion and operational efficiencies.
Overall, Humacyte's performance, strengths, challenges, and opportunities position it for growth and impact in the medical field.

Humacyte reports improved financials and advances FDA approval for HAV

Humacyte's Q1 2024 performance reflects a decrease in net loss, strong financial management, and progress in key clinical trials and product development.
The company's strengths lie in FDA milestones, strategic funding, research focus on high-impact areas, and financial stability.
Challenges include managing operating expenses, financial pressures, trial outcomes uncertainty, and successful market entry post-approval.
Opportunities abound in FDA approval prospects, market expansion, product diversification, and leveraging financial resources for growth initiatives.

Humacyte reports progress in key programs despite FDA delay

Humacyte's Q2 2024 earnings call highlighted progress in key programs, financial challenges due to FDA delay, and optimism for future growth. The company's strong financial position and strategic additions to the Board of Directors bode well for upcoming commercialization efforts.

Humacyte reports Q3 losses, highlights innovation and growth opportunities

Humacyte's Q3 2024 performance reflected significant investment in R&D and G&A expenses, resulting in a net loss of $39.2 million.
Positive trial outcomes and patent approvals underscore the company's innovation and potential for future revenue streams.
While facing financial challenges and regulatory uncertainties, Humacyte's strong cash position and ongoing trials offer opportunities for growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.

Humacyte's acellular tissue engineered vessel (ATEV) shows promise in trauma and dialysis, with positive clinical trial results and potential FDA approval by year-end. Despite FDA delays, Humacyte remains optimistic but faces financial instability, with only $43.6 million in cash, supporting operations for 1.5 quarters. HUMA stock is rated as a moderate "Buy" for high-risk tolerant investors, given the potential for FDA approval and significant market capture in trauma.

Humacyte: Navigating The FDA Uncertainty And ATEV's Potential

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Humacyte, Inc. (HUMA) Is Considered a Good Investment by Brokers: Is That True?

Humacyte's (HUMA) Biologic License Application for its ATEV faces a delay as the FDA extends its review timeline, recognizing the product's potential impact on vascular trauma treatment.

Humacyte's (HUMA) ATEV BLA Review Period Extended by FDA

Humacyte, Inc. (NASDAQ:HUMA ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Lauren Marek - LifeSci Advisors Laura Niklason - President and CEO Dale Sander - CFO and Chief Corporate Development Officer Conference Call Participants Ryan Zimmerman - BTIG Josh Jennings - TD Cowen & Company Allison Bratzel - Piper Sandler Kristen Kluska - Cantor Fitzgerald Bruce Jackson - The Benchmark Company Operator Good afternoon, ladies and gentlemen, and welcome to the Humacyte's Second Quarter Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.

Humacyte, Inc. (HUMA) Q2 2024 Earnings Call Transcript

Friday, the FDA announced it would require additional time to complete its review of Humacyte Inc.'s HUMA Biologic License Application (BLA) for the acellular tissue-engineered vessel (ATEV) in the vascular trauma indication.

Delay Hits Humacyte's Bioengineered Human Tissue Implant For Vascular Trauma Injuries, FDA Extends Time To Review

Humacyte said on Friday the U.S. health regulator has extended review of the company's implant that can act as a replacement for an injured or damaged blood vessel, sending its shares down more than 20% after the bell.

US FDA extends review of Humacyte's blood vessel implant

– 2 nd quarter conference call to be held Tuesday, August 13 th , at 8:30 a.m. ET –

Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma

Meta Data Ltd

CommScope Hld

Emergent BioSolutions

Hawaiian Electric Industries

Q32 Bio Inc

Cassava Sciences Inc

Serve Robotics Inc

The United States' macroeconomic environment was favorable to large-cap companies and unfriendly to small-caps through the first half of 2024. That changed in July.

8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803%

DURHAM, N.C., July 31, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced positive top-line results from the V007 Phase 3 Clinical Trial of the acellular tissue engineered vessel (ATEV) in arteriovenous access for patients with end-stage renal disease. In the Phase 3 trial, the ATEV demonstrated superior function and patency at six and 12 months (co-primary endpoints) compared to autogenous fistula, which is the current standard of care for hemodialysis patients.

Humacyte Acellular Tissue Engineered Vessel (ATEV™) Meets Primary Endpoints in V007 Phase 3 Clinical Trial in Arteriovenous Access for Hemodialysis

Humacyte, Inc. (HUMA) closed the most recent trading day at $8.29, moving -0.72% from the previous trading session.

Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Humacyte, a bioengineering company, went public through a SPAC merger in 2015, with a market value of $1.1 billion. The company has received FDA's RMAT designation for three indications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Humacyte's potential product, Acellular Tissue Engineered Vessel, has shown promise in addressing critical medical needs, with a pending FDA approval decision on August 10th.

Humacyte: Creating New Medical Frontiers With Bioengineered Human Tissue

Rate cuts may finally be upon us. After a tentative few months, inflation is showing signs of faltering and the market is beginning to price in rate cuts coming as early as September.

Three Small-Cap Stocks to Buy Before a September-Rate-Cut Rally

Humacyte is developing HAVs for multiple indications, showing promising clinical outcomes, and receiving FDA RMAT designation for faster approval processes. The market for vascular repairs is large and growing, with Humacyte's HAVs positioned as a potentially superior option to traditional treatments. Financially, Humacyte holds sufficient short-term assets but faces significant long-term liabilities and a potential cash crunch within a year.

Humacyte: Pioneering Vascular Solutions With High-Stakes Potential

DURHAM, N.C., July 16, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, announced the addition of pharmaceutical industry veteran Dr. John P. Bamforth and distinguished health system and academic physician Dr. Keith Anthony (Tony) Jones to the Company's Board of Directors.

Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony Jones

SEATTLE--(BUSINESS WIRE)--Pluristyx, a leading provider of tools, technologies, and services for the development of cellular therapies, is pleased to announce a license agreement with Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale. Humacyte has licensed Pluristyx's clinical-grade PluriBank™ induced Pluripotent Stem Cell (iPSC) line as starting materials for manufacturing insulin-producing cells f.

Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs

Humacyte Inc (NASDAQ: HUMA) opened close to 25% up on Monday after the Food & Drug Administration granted its ATEV a special advanced-therapy designation.  Shares of the biotech firm are still down some 30% versus their year-to-date high.

Humacyte wins special advanced-therapy designation for ATEV

– Third RMAT designation by FDA for ATEV – – RMAT will expedite development of ATEV in PAD – DURHAM, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, has been granted the U.S. Food and Drug Administration's (FDA's) Regenerative Medicine Advanced Therapy (RMAT) designation for patients with advanced peripheral artery disease (PAD).

Humacyte Acellular Tissue Engineered Vessel (ATEV™) Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for Patients with Advanced Peripheral Artery Disease (PAD)

Albertsons Companies

AGCO

Brandywine Realty

Deere & Company

FedEx

Harrow Health Inc

Aberdeen Standard Physical Platinum Shares ETF

Sibanye Stillwater

Texas Pacific Land Trust

Uniti Group

Viking Therapeutics

The "Undercovered" Dozen highlights twelve ideas from the previous month on stocks with limited coverage. Albertsons, Viking Therapeutics, Brandywine Realty Trust, platinum, and more are discussed in this edition. A number of veteran Seeking Alpha analysts are on display in this one. And one of them shares a thesis about their largest portfolio holding at 12%.

The 'Undercovered' Dozen From May 2024

American Superconductor

This week in Cheap Seats: Stocks Under $20 segment, we're taking a look at two stocks that are soaring today: Humacyte Inc (NYSE:HUMA) and American Semiconductor Corp (NASDAQ:AMSC).

2 Stocks Under $20 Making Outsized Moves

Humacyte (NASDAQ: HUMA) stock price has surged hard since I wrote about it in April. It soared to a high of $9.35 on Thursday and is now trading at its highest point since December 2021.

Humacyte (HUMA) stock price is pumping but 1 key risk remain

DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference, in New York, NY on Thursday, June 6, 2024. Management will also be available for one-on-one meetings.

Humacyte to Present at the Jefferies Global Healthcare Conference

While Nancy Pelosi often dominates discussions on insider trades in the US, the year 2024 has seen a shift in focus to her Republican counterpart, Tommy Tuberville. His series of trades, particularly notable for their insider nature, have sparked significant interest.

This stock surged 100% since US Senator bought it 2 months ago

Humacyte's stock price has recently been on an impressive bull run, jumping from $4.50 to $6.50 after management announced Q1 2024 earnings. The company's market cap valuation is currently around $765 million - I believe this could rise >$1bn if the company secures a first commercial approval this year, as is likely. Humacyte focuses on regenerative medicine technology, specifically bioengineered human tissues, and has a Biologics License Application accepted by the FDA for its Human Acellular Vessels.

Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High

DURHAM, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, Dale Sander, Chief Financial Officer, and B.J. Scheessele, Chief Commercial Officer, will represent Humacyte at the following conferences in May.

Humacyte to Participate at Upcoming Investor Conferences in May

Humacyte, Inc. (NASDAQ:HUMA ) Q1 2024 Earnings Conference Call May 10, 2024 8:00 AM ET Company Participants Tom Johnson - Investor Relations, LifeSci Advisors Laura Niklason - Founder, President, Chief Executive Officer Dale Sander - Chief Financial Officer, Chief Corporate Development Officer, Treasurer Heather Prichard - Chief Operating Officer Conference Call Participants Ryan Zimmerman - BTIG Kristen Kluska - Cantor Fitzgerald Bruce Jackson - The Benchmark Company Josh Jennings - TD Cowen Operator Good morning, ladies and gentlemen, and welcome to the Humacyte First Quarter 2024 Results Conference Call. Currently all participants are in a listen-only mode.

News for Humacyte Stock (HUMA)